7
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Efecto de los antimaláricos sobre los diferentes dominios del índice de daño SLICC en pacientes de la cohorte GLADEL Translated title: Effect of antimalarials on the different domains of the SLICC damage index in patients of the GLADEL cohort

      research-article
      , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
      Revista argentina de reumatología
      Sociedad Argentina de Reumatología
      antimaláricos, lupus eritematoso sistémico, daño acumulado, Latinoamérica, antimalarials, systemic lupus erythematosus, damage accrual, Latin America

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objetivos: Estimar el efecto de los antimaláricos (AM) sobre los diferentes dominios del índice de daño SLICC (SDI). Métodos: Se estudiaron pacientes con diagnóstico clínico reciente (≤2 años) de lupus eritematoso sistémico (LES) de la cohorte GLADEL. Variable de estudio: aumento en los dominios del SDI desde el ingreso a la cohorte. Variables independientes: características sociodemográficas, clínicas, laboratorio y tratamientos. El efecto de los AM, como variable dependiente del tiempo, sobre los dominios más frecuentes del SDI (ajustado por factores de confusión) fue examinado con un modelo de regresión de Cox multivariado. Resultados: De 1466 pacientes estudiados, 1049 (72%) recibieron AM con un tiempo medio de exposición de 30 meses (Q1-Q3: 11-57) y 665 pacientes (45%) presentaron daño durante un seguimiento medio de 24 meses (Q1-Q3: 8-55); 301 eventos fueron cutáneos, 208 renales, 149 neuropsiquiátricos, 98 musculoesqueléticos, 88 cardiovasculares y 230 otros. Después de ajustar por factores de confusión, el uso de AM se asoció a un menor riesgo de daño renal (HR 0,652; IC 95%: 0,472-0,901) y en el límite de la significancia estadística (HR 0,701, IC 95%: 0,481-1,024) para el dominio neuropsiquiátrico. Conclusión: En GLADEL, el uso de AM se asoció independientemente a un menor riesgo de daño acumulado renal.

          Translated abstract

          Objective: To assess the effects of antimalarials (AM) over the items of the SLICC Damage Index (SDI). Methods: Patients with recent (≤2 years) diagnosis of systemic lupus erythematosus (SLE) from the GLADEL cohort were studied. End-point: increase in items SDI since cohort entry. Independent variables (socio-demographic, clinical, laboratory and treatment) were included. The effect of AM as a time dependent variable on most frequent SDI items (adjusting for potential confounders) was examined with a multivariable Cox regression model. Results: Of the 1466 patients included in this analysis, 1049 (72%) received AM with a median exposure time of 30 months (Q1-Q3: 11-57). Damage occurred in 665 (45%) patients during a median follow-up time of 24 months (Q1-Q3: 8-55). There were 301 integument, 208 renal, 149 neuropsychiatric, 98 musculoskeletal, 88 cardiovascular and 230 others less frequently represented damages. After adjusting for potential confounders at any time during follow-up, a lower risk of renal damage (HR 0.652; 95% CI: 0.472-0.901) and borderline for neuropsychiatric damage (HR 0.701, 95% CI: 0.481-1.024) was found. Conclusion: In the GLADEL cohort, after adjustment for possible confounding factors, AM were independently associated with a reduced risk of renal damage accrual.

          Related collections

          Most cited references21

          • Record: found
          • Abstract: found
          • Article: not found

          Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L).

          In patients with systemic lupus erythematosus (SLE), hydroxychloroquine prevents disease flares and damage accrual and facilitates the response to mycophenolate mofetil in those with renal involvement. A study was undertaken to determine whether hydroxychloroquine also exerts a protective effect on survival. Patients with SLE from the multiethnic LUMINA (LUpus in MInorities: NAture vs nurture) cohort were studied. A case-control study was performed within the context of this cohort in which deceased patients (cases) were matched for disease duration (within 6 months) with alive patients (controls) in a proportion of 3:1. Survival was the outcome of interest. Propensity scores were derived by logistic regression to adjust for confounding by indication as patients with SLE with milder disease manifestations are more likely to be prescribed hydroxychloroquine. A conditional logistic regression model was used to estimate the risk of death and hydroxychloroquine use with and without the propensity score as the adjustment variable. There were 608 patients, of whom 61 had died (cases). Hydroxychloroquine had a protective effect on survival (OR 0.128 (95% CI 0.054 to 0.301 for hydroxychloroquine alone and OR 0.319 (95% CI 0.118 to 0.864) after adding the propensity score). As expected, the propensity score itself was also protective. Hydroxychloroquine, which overall is well tolerated by patients with SLE, has a protective effect on survival which is evident even after taking into consideration the factors associated with treatment decisions. This information is of importance to all clinicians involved in the care of patients with SLE.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual.

            To examine whether hydroxychloroquine (HCQ) usage is associated with a reduced risk of damage accrual in patients with systemic lupus erythematosus (SLE). Patients (n = 518) meeting the American College of Rheumatology criteria for diagnosis of SLE and with
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort.

              To assess whether hydroxychloroquine can delay renal damage development in lupus nephritis patients. Lupus nephritis patients (n = 256) from the LUpus in MInorities, NAture versus nurture study (n = 635), a multiethnic cohort of African Americans, Hispanics, and Caucasians, age > or =16 years with disease duration or =1 of the following lasting at least 6 months: estimated/measured glomerular filtration rate or =3.5 gm and/or end-stage renal disease, regardless of dialysis or transplantation). Patients with renal damage before T0 were excluded (n = 53). The association between hydroxychloroquine use and renal damage (as defined, or omitting proteinuria) was estimated using Cox proportional regression analyses adjusting for potential confounders. Kaplan-Meier survival curves based on hydroxychloroquine intake or the World Health Organization (WHO) class glomerulonephritis were also derived. Sixty-three (31.0%) of the 203 patients included developed renal damage over a mean +/- SD disease duration of 5.2 +/- 3.5 years. The most frequent renal damage domain item was proteinuria. Patients who received hydroxychloroquine (79.3%) exhibited a lower frequency of WHO class IV glomerulonephritis, had lower disease activity, and received lower glucocorticoid doses than those who did not take hydroxychloroquine. After adjusting for confounders, hydroxychloroquine was protective of renal damage occurrence in full (hazard ratio [HR] 0.12, 95% confidence interval [95% CI] 0.02-0.97, P = 0.0464) and reduced (HR 0.29, 95% CI 0.13-0.68, P = 0.0043) models. Omitting proteinuria provided comparable results. The cumulative probability of renal damage occurrence was higher in those who did not take hydroxychloroquine and those classified as WHO class IV glomerulonephritis (P < 0.0001). After adjusting for possible confounding factors, the protective effect of hydroxychloroquine in retarding renal damage occurrence in systemic lupus erythematosus is still evident.
                Bookmark

                Author and article information

                Contributors
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Journal
                reuma
                Revista argentina de reumatología
                Rev. argent. reumatolg.
                Sociedad Argentina de Reumatología (Buenos Aires, , Argentina )
                0327-4411
                2362-3675
                September 2018
                : 29
                : 3
                : 6-10
                Affiliations
                [04] Birmingham orgnameUniversidad de Alabama EE.UU.
                [18] orgnameUniversidade Federal do Rio Grande do Sul orgdiv1Hospital da Clinicas da Porto Alegre Brasil
                [21] Santiago orgnameUniversidad San Sebastián orgdiv1Facultad de Medicina Chile
                [24] Medellín orgnameUniversidad de Antioquia orgdiv1Facultad de Medicina orgdiv2Grupo de Reumatología Colombia
                [36] San Cristóbal orgnameHospital Central de San Cristóbal Venezuela
                [32] Ciudad de México orgnameCentro Médico ABC México
                [19] Goiania orgnameUniversidade Federal de Goias orgdiv1Faculdade de Medicina Brasil
                [15] Sao Paulo orgnameUniversidade Federal da Sao Paulo (UNIFESP) Brasil
                [26] La Habana orgnameCentro de Investigaciones Médico Quirúrgicas (CIMEQ) Cuba
                [25] Barcelona orgnameHospital Clinic orgdiv1Servicio de Reumatología España
                [01] Rosario orgnameCentro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR) Argentina
                [05] Lima orgnameHospital Nacional Guillermo Almenara Irigoyen Perú
                [29] Guadalajara orgnameHospital General de Occidente de la Secretaría de Salud México
                [07] Ciudad Autónoma de Buenos Aires orgnameHospital Italiano de Buenos Aires orgdiv1Servicio de Clínica Médica orgdiv2Sección de Reumatología Argentina
                [35] Caracas orgnameCentro Nacional de Enfermedades Reumáticas orgdiv1Hospital Universitario de Caracas Venezuela
                [13] Granadero Baigorria orgnameHospital Escuela Eva Perón Argentina
                [22] Santiago orgnameUniversidad de Chile orgdiv1Facultad de Medicina orgdiv2Hospital del Salvador Chile
                [31] Ciudad de México orgnameInstituto Nacional de Cardiología orgdiv1Departamento de Reumatología México
                [10] La Plata orgnameHospital Interzonal General de Agudos General San Martín Argentina
                [30] Ciudad de México orgnameÁngeles del Pedregal México
                [33] Monterrey NL orgnameInstituto Mexicano de Seguro Social orgdiv1Hospital de Especialidades No 25 orgdiv2Servicio de Reumatología Mexico
                [12] Atlanta Georgia orgnameEmory School of Medicine orgdiv1Department of Medicine orgdiv2Division of Rheumatology USA
                [27] Morelia orgnameCentro de Investigación Clínica de Morelia SC México
                [08] Córdoba orgnameCentro Médico de Córdoba orgdiv1Hospital Privado Argentina
                [17] Campinas orgnameUniversidade Estadual da Campinas Brasil
                [06] Lima orgnameUniversidad Científica del Sur Perú
                [11] Córdoba orgnameHospital Nacional de Clínicas orgdiv1Servicio de Reumatología Argentina
                [23] Medellín orgnameCentro Integral de Reumatología orgdiv1Reumalab Colombia
                [28] México DF orgnameInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán orgdiv1Departamento de Inmunología y Reumatología México
                [34] Lima orgnameHospital Nacional Edgardo Rebagliatti Martins Perú
                [14] Mar del Plata orgnameHIGA Dr. Oscar Alende orgdiv1Unidad de Reumatología y Enfermedades Autoinmunes Sistémicas Argentina
                [03] orgnameGLADEL
                [16] Sao Paulo orgnameUniversidade da Sao Paulo Brasil
                [02] Rosario orgnameHospital Provincial de Rosario Argentina
                [09] Ciudad Autónoma de Buenos Aires orgnameInstituto de Investigaciones Médicas Argentina
                [20] Pernambuco orgnameUniversidade Federal da Pernambuco Brasil
                Article
                S2362-36752018000300002
                9db1d6bb-c276-4794-942c-a81f557dac13

                This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

                History
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 25, Pages: 5
                Product

                SciELO Argentina

                Categories
                Artículo original

                antimaláricos,lupus eritematoso sistémico,daño acumulado,Latinoamérica,antimalarials,systemic lupus erythematosus,damage accrual,Latin America

                Comments

                Comment on this article